伦敦乳腺病灶介电扫描研究:MARIA® M6 乳腺成像系统的结果
前瞻性单中心干预性上市后器械研究纳入389例患者,57例(47%)恶性病灶的MARIA®信号与乳腺癌对应,浸润性癌对应率50%高于原位癌29%,乳腺密度升高未见对应率下降,中央扫描区域和小病灶信号对应减少,MARIA®扫描耐受良好。
要点
- 47%的乳腺癌MARIA®信号与恶性病灶对应,浸润性癌50%高于原位癌29%。
- 乳腺密度升高未见信号对应率下降。
- 中央扫描区域和小病灶的信号对应减少。
核心结论
- 作者认为MARIA®信号在47%的受检乳腺癌中与恶性病灶对应,该研究是此类技术迄今最大规模的研究,展示了MARIA® M6版本的成效与局限。
研究设计与样本
- 前瞻性、单中心、干预性、上市后器械研究,2018年5月至2020年3月招募,389例患者入组、6例排除,114例乳腺癌患者(2例双侧、5例多中心),MARIA®通过射频天线阵列测量信号衰减和后向散射构建组织介电值三维图。
诊断标准与关键数值
- 将信号高于背景或形状独特的区域视为病灶对应候选,每侧乳腺最多标注4个候选区域并按代表真实病灶的可能性排序;57例(47%)恶性病灶显示MARIA®信号与癌症对应,浸润性癌对应率50%、原位癌29%,乳腺密度升高未见对应率下降,中央扫描区域和小病灶信号对应减少。
临床应用与阅片要点
- MARIA®扫描耐受良好;阅片时需注意中央扫描区域和小病灶的信号对应减少,每侧乳腺最多标注4个候选区域并按可能性排序。
局限性
- 中央扫描区域和小病灶的信号对应减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Determine the proportion of breast cancers for which MARIA® findings correspond to the cancer, with stratification by breast density and histological type. Investigate performance in symptomatic lesions. Gain patient feedback on experience with MARIA®.
METHODS: MARIA® uses a radio frequency antennae array to measure signal attenuation and back scatter to build up a 3D map of tissue dielectric values. The study was a prospective, single-centre, interventional, post-approval device study.
RECRUITMENT: Patients were eligible if they were attending symptomatic breast clinic or had confirmed or suspected breast cancer from any referral source. Recruitment between May 2018 and March 2020.
READING: Regions of higher signal compared to background or distinct by shape were considered candidates for lesion correspondence. Up to 4 candidate regions per breast were annotated in likelihood order for representing a true lesion.
RESULTS: 389 patients were recruited, and 6 excluded. 114 patients recruited with breast cancers (2 bilateral, 5 multicentric). 57 (47%) malignant lesions showed correspondence between the MARIA® signal and the cancer. Higher correspondence was seen in invasive (50%) than in situ (29%) disease. There was no reduction in correspondence at higher breast density. Reduced signal correspondence in the central scan volume and for small lesions. MARIA® scanning was well tolerated.
CONCLUSIONS: We believe that MARIA® signal corresponds to a malignant lesion in 47% of breast cancers examined.
ADVANCES IN KNOWLEDGE: Our study, the largest to date for this type of technology, demonstrates successes and limitations of this MARIA® M6 version.
引用
- Sidebottom R, Webb D, Bishop B, et al. Results for the London investigation into dielectric scanning of lesions study of the MARIA® M6 breast imaging system. Br J Radiol. 2024. PMID: 38268437. doi:10.1093/bjr/tqae013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。